MiMedx Group (MDXG) Stock: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$4.57
-0.03 (-0.65%)
▼
5d:
+3.16%
30d:
+6.78%
90d:
+23.85%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MDXG shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MDXG shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.01
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $4.57, which is considered extended relative to its 30-day fair value range of $4.24 to $4.53. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.9) compared to its historical average (26.9). Remarkably, the market is currently pricing in an annual earnings decline of 5.3% over the next few years. This pessimistic expectation contrasts with the company's recent 99.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, MDXG is in a strong uptrend. Immediate support is located at $4.34, while resistance sits at $4.73.
Market Sentiment: MDXG scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.40 (+61.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDXG is in a strong uptrend. Immediate support is located at $4.34, while resistance sits at $4.73.
Market Sentiment: MDXG scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.40 (+61.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.24 -
$4.53
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 61.9% below Wall St target ($7.40)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.24 -
$4.53
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.35
Resistance Level
$4.73
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.85
Wall Street Target
$7.40
(+61.9%)
Revenue Growth (YoY)
-34.7%
Earnings Growth (YoY)
99.5%
Profit Margin
1.8%
Valuation Discount vs History
-5.3% cheaper
PE vs Historical
22.9 vs 26.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.3%
(market-implied from PE analysis)
1-Year Target
$4.33
(-5%)
2-Year Target
$4.10
(-10%)
3-Year Target
$3.88
(-15%)
3-Yr Target (if PE normalizes)
(PE: 23→27)
$4.57
(0%)
📈
Valuation based on Current Earnings
Forward PE: 19.53 | Forward EPS (Implied): $0.23
Bull Case
$5.52
(+21%)
Analyst growth 15.0%, PE expands to 20.5
Base Case
$4.57
(0%)
Market implied 0.0%, PE stable at 19.5
Bear Case
$3.50
(-24%)
Severe decline -15.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.9 to 26.9
Stabilization Target:
$5.38
(+17.7%)
PE Expansion Potential:
+17.7%
Share & Embed Analysis
Last updated: September 13, 2026 3:26 AM ET
Data refreshes hourly during market hours. Next update: 4:26 AM
Data refreshes hourly during market hours. Next update: 4:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
